Recruiting

PMR with Corticosteroids

Sponsor:

Dartmouth-Hitchcock Medical Center

Code:

NCT07748195

Conditions

Polymyalgia Rheumatica (PMR)

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Polymyalgia Rheumatica (PMR) is treated with corticosteroids; however, long-term treatment is not feasible due to side effects. Withdrawal of corticosteroids causes a subset of patients to relapse, and there is no current way to understand what underlies this. Our research team has preliminary data from a small clinical study that indicates that different immune effector dynamics during the tapering of steroids correlate with relapse. This was achieved using the DNA methylation-specific immune cell profiling methods that Dr. Christensen has pioneered. What is proposed is a larger prospective study of 50 PMR patients to validate differences in CD4 and CD8 memory cells as a predictor of relapse. Finally, we also focus on the Glucocorticoid Methylation Index (GCMI), which is a collection of 28 CpG islands that are methylated in response to corticosteroids. This will allow our team to determine the predictive power of the GCMI for PMR.

Conditions

Polymyalgia Rheumatica (PMR)

Study ID

NCT07748195

Start date

Aug 31, 2026

Status verified date

Apr, 2026

Completion date

Apr 1, 2027

Anticipated

Primary completion date

Apr 1, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50 - 70+

Healthy Volunteers: Accepted

Inclusion Criteria:

Anyone ≥50-89 years old Taking ≥10mg of prednisone or prednisone equivalent at time of enrollment with a stable disease normal ESR and CRP (inflammation markers) which would indicate presence of inflammation or not

  • CRP: <1.0 mg/dL (some labs report in mg/L → normal is usually <3 mg/L)
  • ESR:
  • Men ≥50 years: 0-20 mm/hr
  • Women ≥50 years: 0-30 mm/hr Have a PMR diagnosis Able to provide written consent

Exclusion Criteria:

  • History of concomitant Giant cell arteritis (GCA) any other rheumatological disorders like lupus, arthritis (psoriatic, osteo), scleroderma, sjogrens Active malignancy- presence of tumor by imaging or labs Infection- infection can cause increased levels of innate immune cells making it difficult to differentiate between disease and infection recent surgery- within the past 6 months

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Arms

PMR diagnosed

individuals who have a PMR diagnosis

Healthy Volunteers

Healthy individuals, without a PMR diagnosis, which will allow age and sex matches with the PMR diagnosed cohort.

Primary outcome measure

  • Understanding what the exact triggers for immune activation, the specific antigens involved, and the mechanisms underlying disease relapses and glucocorticoid resistance [ Time Frame: 12 months ]

Central Contacts and Locations

Locations

Dartmouth Hitchcock Medical Center

Recruiting

Lebanon, New Hampshire, United States, 03766

Contacts

More Information

Sponsor

Dartmouth-Hitchcock Medical Center

Last update posted

Nov 16, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.